Phase 3 Clinical Trials With Primary Completion Dates in February 2024

This is a list of Phase 3 trials with primary completion dates in February 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ALVOAlvotech2024-02-01Phase 3NCT05986786Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease
ALVOAlvotech2024-02-01Phase 3NCT05842213Comparative, Multicenter Study in Subjects With Rheumatoid Arthritis, ALVOFLEX
CASBFCanSino Biologics Inc.2024-02-01Phase 3NCT05951725A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
CRNXCrinetics Pharmaceuticals, Inc.2024-02-01Phase 3NCT05192382A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
EIGREiger BioPharmaceuticals, Inc.2024-02-01Phase 3NCT04727424Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
ITCIIntra-Cellular Therapies, Inc.2024-02-01Phase 3NCT04985942Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
MNKDMannKind Corporation2024-02-01Phase 3NCT04974528Afrezza® INHALE-1 Study in Pediatrics
PTGXProtagonist Therapeutics, Inc.2024-02-01Phase 3NCT05210790A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
RAREUltragenyx Pharmaceutical Inc.2024-02-01Phase 3NCT05139316A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)